PRACA PRZEGLĄDOWA
Obwodowy układ nerwowy w pierwotnym zespole Sjögrena
Więcej
Ukryj
Data publikacji online: 26-06-2013
Reumatologia 2013;51(3):202-209
SŁOWA KLUCZOWE
STRESZCZENIE
Zespół Sjögrena jest układową autoimmunizacyjną chorobą, w przebiegu której dochodzi do uszkodzenia nie tylko gruczołów wydzielania zewnętrznego, lecz także innych narządów i tkanek. Zmiany w różnych odcinkach obwodowego układu nerwowego powodują powstanie wielu typów klinicznych neuropatii. Najczęściej spotykane neuropatie w pierwotnym zespole Sjögrena to: czuciowa dystalna symetryczna polineuropatia spowodowana degeneracją aksonów, czuciowa neuropatia z ataksją na skutek uszkodzenia neuronów zwojów korzeni rdzeniowych oraz bolesna dyzestezja wywołana zmianami w drobnych nerwach epidermalnych. W artykule opisano różnorodne objawy kliniczne wynikające z uszkodzenia obwodowego układu nerwowego w przebiegu pierwotnego zespołu Sjögrena, ze zwróceniem szczególnej uwagi na częstość ich występowania oraz różną patogenezę, leczenie i odmienne rokowanie.
REFERENCJE (29)
1.
Al-Hashimi I. Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management. Drugs Aging 2005; 22: 887-899. .
2.
Chai J, Logigian EL. Neurological manifestations of primary Sjögren’s syndrome. Curr Opin Neurol 2010; 23: 509-513.
3.
Pavlakis PP, Alexopoulos H, Kosmidis ML, et al. Peripheral neuropathies in Sjögren's syndrome: A critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012; 39: 27-33. .
4.
Go/ransson LG, Herigstad A, Tjensvoll AB, et al. Peripheral neuropathy in primary Sjögren syndrome. A population-based study. Arch Neurol 2006; 63: 1612-1615.
5.
Mellgren SI, Göransson LG, Omdal R. Primary Sjögren's syndrome associated neuropathy. Can J Neurol Sci 2007; 34: 280-287.
6.
Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83: 280-291.
7.
Se`ne D, Jallouli M, Lefaucheur JP, et al. Peripheral neuropathies associated with primary Sjögren syndrome: immunologic profiles of nonataxic sensory neuropathy and sensorimotor neuropathy. Medicine (Baltimore) 2011; 90: 133-138.
8.
Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical ma-nifestations in Sjögren's syndrome-associated neuropathy. Brain 2005; 128: 2518-2534.
9.
Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008; 87: 210-219.
10.
Terrier B, Lacroix C, Guillevin L, et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome-related neuropathy. Arthritis Rheum 2007; 57: 1520-1529.
11.
Ramos-Casals M, Anaya JM, García-Carrasco M, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 2004; 83: 96-106.
12.
Murata Y, Maeda K, Kawai H, et al. Antiganglion neuron antibodies correlate with neuropathy in Sjögren's syndrome. Neuroreport 2005; 16: 677-681.
13.
Witte T. Antifodrin Antibodies in Sjögren’s Syndrome. A Review Ann N Y Acad Sci 2005; 1051: 235-239.
14.
Dawson LJ, Stanbury J, Venn N, et al. Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum 2006; 54: 1165-1173.
15.
Mandl T, Hammar O, Theander E, et al. Autonomic nervous dysfunction development in patients with primary Sjögren’s syndrome: a follow-up study. Rheumatology (Oxford) 2010; 49: 1101-1106.
16.
Tobón GJ, Pers JO, Devauchelle-Pensec V, et al. Neurological disorders in Primary Sjögren's Syndrome. Autoimmune Dis 2012; 2012: 645967.
17.
Bhanji RA, Eystathioy T, Chan EK, et al. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 2007; 125: 247-256. .
18.
Ruiz-Tíscar JL, López-Longo FJ, Sánchez-Ramón S, et al. Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjögren's syndrome. Ann N Y Acad Sci 2005; 1050: 210-216.
19.
Ruffatti A, Ostuni P, Grypiotis P, et al. Sensitivity and specificity for primary Sjögren's syndrome of IgA and IgG anti-alpha-fodrin antibodies detected by ELISA. J Rheumatol 2004; 31: 504-507.
20.
Newton JL, Frith J, Powell D, et al. Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome. Ann Rheum Dis 2012; 71: 1973-1979.
21.
Morozumi S, Kawagashira Y, Iijima M, et al. Intravenous immunoglobulin treatment for painful sensory neuropathy associated with Sjögren's syndrome. J Neurol Sci 2009; 29: 57-61.
22.
Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y. Sjögren's syndrome, the old and the new. Best Pract Res Clin Rheumatol 2012; 26: 105-117.
23.
Marbini B, Pavesi G, Cattaneo L, Marbini A. Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. J Neurol 2002; 249: 777-779.
24.
Landete L, Blasco R. Sjögren syndrome and subacute demyelinating polyradiculopathy: an unusual association. Rev Neurol 1998; 27: 995-997.
25.
Gemignani F, Marbini A, Pavesi G, et al. Peripheral neuropathy associated with primary Sjögren's syndrome. J Neurol Neurosurg Psychiatry 1994; 57: 983-986.
26.
Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012; 71: 84-87.
27.
Andonopoulos AP, Christodoulou J, Ballas C, et al. Autonomic cardiovascular neuropathy in Sjögren's syndrome. A controlled study. J Rheumatol 1998; 25: 2385-2388.
28.
Griffin JW, Cornblath DR, Alexander E, et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome. Ann Neurol 1990; 27: 304-315.
29.
Waterschoot MP, Guerit JM, Lambert M, de Barsy T. Bilateral tonic pupils and polyneuropathy in Sjögren's syndrome: a common pathophysiological mechanism? Eur Neurol 1991; 31: 114-116.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.